Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Trial Profile

Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VESTED
  • Most Recent Events

    • 14 Dec 2018 Planned End Date changed from 1 Nov 2020 to 31 Jul 2020.
    • 14 Dec 2018 Planned primary completion date changed from 1 Nov 2020 to 31 Jul 2020.
    • 02 Jan 2018 Planned number of patients changed from 549 to 639.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top